Related Experiment Video
Updated: Oct 26, 2025
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
Tanner Fullmer1, Maria E Cabanillas2, Mark Zafereo1
1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Abstract:
Iodine-resistant cancers account for the vast majority of thyroid related mortality and, until recently, there were limited therapeutic options. However, over the last decade our understanding of the molecular foundation of thyroid function and carcinogenesis has driven the development of many novel therapeutics. These include FDA approved tyrosine kinase inhibitors and small molecular inhibitors of VEGFR, BRAF, MEK, NTRK and RET, which collectively have significantly changed the prognostic outlook for this patient population. Some therapeutics can re-sensitize de-differentiated cancers to iodine, allowing for radioactive iodine treatment and improved disease control. Remarkably, there is now an FDA approved treatment for BRAF-mutated patients with anaplastic thyroid cancer, previously considered invariably and rapidly fatal. The treatment landscape for iodine-resistant thyroid cancer is changing rapidly with many new targets, therapeutics, clinical trials, and approved treatments. We provide an up-to-date review of novel therapeutic options in the treatment of iodine-resistant thyroid cancer.
Insights
Novel therapeutics, including targeted inhibitors, are transforming outcomes for iodine-resistant thyroid cancer. These treatments offer new hope, even for aggressive forms like anaplastic thyroid cancer, by re-sensitizing tumors to radioactive iodine therapy.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Iodine-resistant thyroid cancer is a major cause of mortality, historically with limited treatment options.
- Recent advances in understanding thyroid cancer molecular pathways have spurred the development of novel therapeutics.
- Anaplastic thyroid cancer, particularly BRAF-mutated types, was previously considered uniformly fatal.
Purpose of the Study:
- To review the latest therapeutic strategies for iodine-resistant thyroid cancer.
- To highlight the impact of novel molecularly targeted therapies on patient prognosis.
- To discuss emerging treatments and clinical trials in this field.
Main Methods:
- Review of recent scientific literature and clinical trial data.
- Analysis of FDA-approved targeted therapies for thyroid cancer.
- Examination of molecular targets including VEGFR, BRAF, MEK, NTRK, and RET.
Main Results:
- Several FDA-approved tyrosine kinase inhibitors and small molecule inhibitors have significantly improved outcomes.
- Some therapies can re-sensitize dedifferentiated thyroid cancers to radioactive iodine.
- A new FDA-approved treatment is now available for BRAF-mutated anaplastic thyroid cancer.
Conclusions:
- The treatment landscape for iodine-resistant thyroid cancer is rapidly evolving with numerous new therapeutic options.
- Targeted therapies and potential re-sensitization to radioactive iodine offer improved disease control and survival.
- Ongoing research and clinical trials continue to expand treatment possibilities for this challenging malignancy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
01:20Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...